Lionco Pharmaceutical Group Co.,Ltd.
SSE:603669.SS
5.23 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 379.78 | 196.831 | 289.263 | 740.328 | 1,001.002 | 1,635 | 1,669.431 | 1,005.08 | 478.589 | 550.645 | 576.402 | 494.246 | 468.28 | 271.547 |
| Cost of Revenue
| 201.737 | 104.967 | 93.115 | 152.686 | 155.655 | 223.155 | 201.994 | 200.79 | 202.617 | 220.149 | 225.434 | 202.075 | 181.102 | 149.596 |
| Gross Profit
| 178.043 | 91.865 | 196.148 | 587.642 | 845.348 | 1,411.845 | 1,467.437 | 804.29 | 275.971 | 330.496 | 350.968 | 292.171 | 287.178 | 121.952 |
| Gross Profit Ratio
| 0.469 | 0.467 | 0.678 | 0.794 | 0.845 | 0.864 | 0.879 | 0.8 | 0.577 | 0.6 | 0.609 | 0.591 | 0.613 | 0.449 |
| Reseach & Development Expenses
| 26.665 | 29.125 | 31.625 | 22.775 | 20.365 | 38.044 | 24.299 | 47.403 | 29.341 | 38.576 | 36.773 | 42.977 | 42.761 | 0 |
| General & Administrative Expenses
| 24.2 | 16.313 | 13.169 | 16.591 | 18.23 | 17.819 | 17.932 | 22.571 | 31.025 | 31.463 | 26.652 | 18.159 | 29.227 | 33.134 |
| Selling & Marketing Expenses
| 136.375 | 112.785 | 236.619 | 423.914 | 624.509 | 1,092.355 | 1,215.005 | 538.862 | 54.386 | 55.663 | 79.003 | 69.142 | 60.11 | 22.237 |
| SG&A
| 160.576 | 129.098 | 249.788 | 440.505 | 642.74 | 1,110.175 | 1,232.937 | 561.433 | 85.412 | 87.127 | 105.656 | 87.3 | 89.336 | 55.371 |
| Other Expenses
| 119.571 | 82.623 | 78.852 | 54.736 | -11.102 | 38.111 | -4.815 | -1.835 | 48.644 | 6.351 | 21.829 | 23.022 | 10.725 | 7.065 |
| Operating Expenses
| 306.812 | 240.845 | 360.265 | 518.016 | 652.003 | 1,186.329 | 1,268.399 | 635.657 | 164.096 | 170.204 | 186.547 | 163.058 | 159.205 | 57.648 |
| Operating Income
| -128.769 | -148.981 | -164.117 | 71.129 | 180.748 | 222.626 | 209.006 | 181.937 | 130.619 | 172.354 | 163.902 | 129.999 | 124.21 | 65.4 |
| Operating Income Ratio
| -0.339 | -0.757 | -0.567 | 0.096 | 0.181 | 0.136 | 0.125 | 0.181 | 0.273 | 0.313 | 0.284 | 0.263 | 0.265 | 0.241 |
| Total Other Income Expenses Net
| 1.04 | -1.974 | -0.131 | -0.648 | -1.488 | 0.299 | -4.815 | -1.835 | 48.644 | 4.257 | 21.127 | 22.996 | 10.716 | 7.064 |
| Income Before Tax
| -127.729 | -150.955 | -188.806 | 70.48 | 179.26 | 222.924 | 204.19 | 180.102 | 177.167 | 176.612 | 185.029 | 152.995 | 134.926 | 72.464 |
| Income Before Tax Ratio
| -0.336 | -0.767 | -0.653 | 0.095 | 0.179 | 0.136 | 0.122 | 0.179 | 0.37 | 0.321 | 0.321 | 0.31 | 0.288 | 0.267 |
| Income Tax Expense
| 3.035 | 0.541 | 6.942 | 4.577 | 19.187 | 21.332 | 21.487 | 19.096 | 23.242 | 26.917 | 35.171 | 38.197 | 39.752 | 16.733 |
| Net Income
| -130.764 | -151.496 | -195.748 | 65.904 | 160.073 | 201.592 | 182.704 | 161.005 | 153.925 | 149.694 | 149.858 | 114.799 | 95.173 | 55.754 |
| Net Income Ratio
| -0.344 | -0.77 | -0.677 | 0.089 | 0.16 | 0.123 | 0.109 | 0.16 | 0.322 | 0.272 | 0.26 | 0.232 | 0.203 | 0.205 |
| EPS
| -0.18 | -0.21 | -0.27 | 0.092 | 0.22 | 0.28 | 0.26 | 0.22 | 0.22 | 0.23 | 0.28 | 0.22 | 0.18 | 0.41 |
| EPS Diluted
| -0.18 | -0.21 | -0.27 | 0.085 | 0.21 | 0.28 | 0.26 | 0.22 | 0.22 | 0.23 | 0.28 | 0.22 | 0.18 | 0.41 |
| EBITDA
| -64.007 | -90.79 | -134.372 | 132.72 | 251.865 | 288.779 | 249.412 | 215.062 | 209.767 | 208.299 | 201.187 | 141.65 | 142.611 | 63.291 |
| EBITDA Ratio
| -0.169 | -0.461 | -0.465 | 0.179 | 0.252 | 0.177 | 0.149 | 0.214 | 0.438 | 0.378 | 0.349 | 0.287 | 0.305 | 0.233 |